{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-046155","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.417496+00:00","generated_at":"2026-05-22T04:54:48.226705+00:00","sec_items":["1.01","2.02","3.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Elutia Issues Shares to Ligand, Amends SWK Loan, and Reports 84% Sequential EluPro Growth","bullets":["Issued 1,105,528 shares to Ligand Pharmaceuticals to satisfy $2.2 million in royalty obligations.","Amended SWK credit facility allowing full PIK interest in May 2025 and potential $5.0 million additional term loan.","Reported Q1 2025 net sales of $6.0 million; BioEnvelope sales up 31% year-over-year to $3.1 million driven by 84% sequential EluPro growth.","Entered partnership with Boston Scientific expected to accelerate EluPro adoption starting Q2 2025.","Cash balance of $17.4 million as of March 31, 2025; raised $15.0 million in gross proceeds from direct offering."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-046155","json":"https://secwatch.observer/filing/0001104659-25-046155.json","markdown":"https://secwatch.observer/filing/0001104659-25-046155.md","text":"https://secwatch.observer/filing/0001104659-25-046155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465925046155/0001104659-25-046155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465925046155/tm2514493d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-22T04:54:48.226705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}